60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report report published on Friday morning,Benzinga reports.

60 Degrees Pharmaceuticals Price Performance

SXTP opened at $0.90 on Friday. The firm has a fifty day moving average price of $1.09 and a 200 day moving average price of $0.72. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $18.36. The stock has a market cap of $1.67 million, a P/E ratio of -0.09 and a beta of 4.78.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.